Literature DB >> 15385463

Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Willy K Tonui1, J Santiago Mejia, Lisa Hochberg, M Lamine Mbow, Jeffrey R Ryan, Adeline S T Chan, Samuel K Martin, Richard G Titus.   

Abstract

The potential of Leishmania major culture-derived soluble exogenous antigens (SEAgs) to induce a protective response in susceptible BALB/c mice challenged with L. major promastigotes was investigated. Groups of BALB/c mice were immunized with L. major SEAgs alone, L. major SEAgs coadministered with either alum (aluminum hydroxide gel) or recombinant murine interleukin-12 (rmIL-12), L. major SEAgs coadministered with both alum and rmIL-12, and L. major SEAgs coadministered with Montanide ISA 720. Importantly and surprisingly, the greatest and most consistent protection against challenge with L. major was seen in mice immunized with L. major SEAgs alone, in the absence of any adjuvant. Mice immunized with L. major SEAgs had significantly smaller lesions that at times contained more than 100-fold fewer parasites. When lymphoid cells from L. major SEAg-immunized mice were stimulated with leishmanial antigen in vitro, they proliferated and secreted a mixed profile of type 1 and type 2 cytokines. Finally, analyses with Western blot analyses and antibodies against three surface-expressed and secreted molecules of L. major (lipophosphoglycan, gp46/M2/PSA-2, and gp63) revealed that two of these molecules are present in L. major SEAgs, lipophosphoglycan and the molecules that associate with it and gp46/M2/PSA-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385463      PMCID: PMC517560          DOI: 10.1128/IAI.72.10.5654-5661.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Authors:  Jerome Aucouturier; L Dupuis; S Deville; S Ascarateil; V Ganne
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

2.  Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis.

Authors:  Jeffrey R Ryan; Anthony M Smithyman; G-Halli Rajasekariah; Lisa Hochberg; John M Stiteler; Samuel K Martin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Identification of an infective stage of Leishmania promastigotes.

Authors:  D L Sacks; P V Perkins
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

4.  Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication.

Authors:  D Wolday; H Akuffo; A Demissie; S Britton
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.

Authors:  A H Noormohammadi; H Hochrein; J M Curtis; T M Baldwin; E Handman
Journal:  Vaccine       Date:  2001-07-16       Impact factor: 3.641

6.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

Authors:  C S Hsieh; S E Macatonia; C S Tripp; S F Wolf; A O'Garra; K M Murphy
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

8.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.

Authors:  J L Maryanski; J Van Snick; J C Cerottini; T Boon
Journal:  Eur J Immunol       Date:  1982-05       Impact factor: 5.532

Review 9.  Vaccines for parasitic and bacterial diseases.

Authors:  Steven G Reed; Antonio Campos-Neto
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Insight into a conserved lifestyle: protein-carbohydrate adhesion strategies of vector-borne pathogens.

Authors:  Rhoel R Dinglasan; Marcelo Jacobs-Lorena
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

3.  Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs.

Authors:  A R Khabiri; F Bagheri; M Assmar
Journal:  Parasitol Res       Date:  2006-09-30       Impact factor: 2.289

4.  In vivo efficacy of oral and intraperitoneal administration of extracts of Warburgia ugandensis (Canellaceae) in experimental treatment of Old World cutaneous leishmaniasis caused by Leishmania major.

Authors:  Peter Kamau Ngure; Zipporah Ng'ang'a; Johnstone Ingonga; Geoffrey Rukunga; Willy Kiprotich Tonui
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-03-07

5.  An experimental approach for the identification of conserved secreted proteins in trypanosomatids.

Authors:  Rosa M Corrales; Françoise Mathieu-Daudé; Déborah Garcia; Simone F Brenière; Denis Sereno
Journal:  J Biomed Biotechnol       Date:  2010-01-17

6.  Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate.

Authors:  Kris I Orsborn; Lisa F Shubitz; Tao Peng; Ellen M Kellner; Marc J Orbach; Paul A Haynes; John N Galgiani
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

Review 7.  Understanding Leishmania parasites through proteomics and implications for the clinic.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Proteomics       Date:  2018-05-02       Impact factor: 3.940

8.  Leishmania donovani Secretory Mevalonate Kinase Regulates Host Immune Response and Facilitates Phagocytosis.

Authors:  Tanvir Bamra; Taj Shafi; Sushmita Das; Manjay Kumar; Manas Ranjan Dikhit; Ajay Kumar; Ashish Kumar; Kumar Abhishek; Krishna Pandey; Abhik Sen; Pradeep Das
Journal:  Front Cell Infect Microbiol       Date:  2021-04-26       Impact factor: 5.293

9.  A review of adjuvants for Leishmania vaccine candidates.

Authors:  Joshua M Mutiso; John C Macharia; Michael M Gicheru
Journal:  J Biomed Res       Date:  2010-01

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.